Development of a Communication Tool between Patients and Physicians for Recognizing COPD Exacerbations in Japan.


Journal

COPD
ISSN: 1541-2563
Titre abrégé: COPD
Pays: England
ID NLM: 101211769

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 17 7 2023
pubmed: 13 7 2023
entrez: 13 7 2023
Statut: ppublish

Résumé

In Japan, exacerbations are underreported compared with other countries, possibly due in part to a failure to recognize them. This study aimed to create a simple chronic obstructive pulmonary disease (COPD) Exacerbation Recognition Tool (CERT-J) specifically for Japanese patients. Patients ≥40 years with confirmed COPD or asthma-COPD overlap were included. Focus groups were held to identify words and phrases used by patients to describe symptoms associated with an exacerbation, resulting in candidate items being identified. Following cognitive debriefing, the items were refined based on item frequency, level of endorsement and effect of demographic factors. Exploratory factor analysis (EFA) was then performed to inform an expert panel's choice of items to form the new tool. A total of 41 patients were included in the focus groups and nine patients performed the cognitive debrief. Following this, the expert panel identified 26 items for testing in a further 100 patients (mean age 72 years, forced expiratory volume in 1 s 54.8% predicted and 1.8 exacerbations in the preceding 12 months). Eleven items were associated with breathlessness or activity limitation and seven of these were the most frequently endorsed. EFA identified four factors, with one (breathlessness) being dominant. The expert panel recommended that the CERT-J should include six items: breathlessness and activity limitation (3 items), cough (1 item) and phlegm (2 items). The final CERT-J should benefit patients with COPD by providing them with an increased understanding and recognition of exacerbations.

Identifiants

pubmed: 37439578
doi: 10.1080/15412555.2023.2219742
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

216-223

Auteurs

Paul Jones (P)

GSK, Brentford, Middlesex, UK.

Osamu Hataji (O)

Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.

Yoshimi Suzukamo (Y)

Department of Physical Medicine and Rehabilitation, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Bruce Crawford (B)

Real World Evidence, Syneos Health, Tokyo, Japan.

Yoko Sakai (Y)

Real World Evidence, Syneos Health, Tokyo, Japan.

Takeo Ishii (T)

Value Evidence Outcomes Respiratory Department, Japan Medical & Development, GSK K.K., Tokyo, Japan.

Keiko Sato (K)

Value Evidence Outcomes Respiratory Department, Japan Medical & Development, GSK K.K., Tokyo, Japan.
Information Technology Center, The University of Tokyo, Tokyo, Japan.

Eri Sasaki (E)

Value Evidence Outcomes Respiratory Department, Japan Medical & Development, GSK K.K., Tokyo, Japan.

Kenichi Hashimoto (K)

Value Evidence Outcomes Respiratory Department, Japan Medical & Development, GSK K.K., Tokyo, Japan.

Toru Oga (T)

Kawasaki Medical School, Kurashiki, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH